ClinConnect ClinConnect Logo
Search / Trial NCT05051618

Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis

Launched by UNIVERSITY OF ILLINOIS AT CHICAGO · Sep 10, 2021

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Multiple Sclerosis Ms Depression Mdd Exercise Physical Activity Intervention Behavior

ClinConnect Summary

This clinical trial is studying how different exercise programs can help manage depression in people with multiple sclerosis (MS). Specifically, it will compare an exercise training program called POWER-MS with a stretching program called FLEX-MS. The goal is to see which program is more effective in reducing symptoms of major depressive disorder (MDD) in participants aged 18 to 64 who have both MS and depression. A total of 146 people will join this study.

To participate, individuals must have a confirmed diagnosis of MS and MDD, be able to communicate in English, and have access to the internet and email. They should not have had a relapse or received steroid treatment in the past 30 days, and they should be able to engage in the exercise activities safely. Participants will be asked to complete questionnaires, wear a device to track their activity, and undergo some tests. This study will provide participants with an opportunity to potentially improve their mental health while being part of important research.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • Physical confirmed diagnosis of Multiple Sclerosis (MS)
  • Diagnosis of Major Depressive Disorder (MDD) - see below (MINI)
  • English as primary language
  • Eligible age (between 18 and 64 years old)
  • Relapse and steroid free in past 30 days
  • Internet and email access
  • Willingness to complete the testing and questionnaires, wear the accelerometer, undergo randomization, and engage in exercise testing
  • Exclusion Criteria
  • Godin Leisure Time Exercise Questionnaire (GLTEQ): Exclude if health contribution score of 14 units or more. This assessment is administered to confirm insufficient baseline physical activity (i.e., not meeting current PA guidelines)
  • Patient Determined Disease Steps (PDDS): Exclude if score above '2' (i.e., greater than mild ambulatory disability). This assessment is administered as the proposed intervention focuses on walking as main modality for exercise training. The scale asks the participant to describe their walking situation on a scale of 0 to 8; where lower scores indicate better walking ability.
  • Beck Depression Inventory-Fast Screen (BDI-FS): Exclude if a score less than '4'. The scale measures depression and those with a score of '4' or below likely have very mild depression resulting in floor effects and/or spontaneous remission.
  • Physical Activity Readiness Questionnaire (PAR-Q): Exclude if more than one yes/affirmative response on this 7-item self-report assessment. This assessment is administered to exclude those individuals who are at a moderate to high risk for contraindications of injury or possible death when undertaking strenuous or maximal exercise. This is a 7-item self-report tool where more than one yes/affirmative response indicates that an individual is not recommended to engage in physical activity within the capacity of this study. Those scoring more than one yes/affirmative response will be further advised to seek medical guidance before becoming more physically active.
  • Telephone Interview for Cognitive Status (TICS-M): Exclude if scores less than 18. This assessment is administered to ensure that all participants can adequately follow directions. The application of the TICS-M is to ensure that participants do not have severe cognitive impairment that might preclude the ability to adhere to the conditions, understand intervention content, and interact with behavior coaches.
  • MINI International Neuropsychiatric Interview (version 7.0.2) based on the Diagnostic and Statistical Manual of Mental Disorders V (DSM-V): Include those who meet the criteria for MDD, but exclude for other severe mental illness (obsessive-compulsive disorder, schizophrenia, bipolar or other psychotic disorders) as indicated by the MINI; these persons would require more intensive mental health treatment.

About University Of Illinois At Chicago

The University of Illinois at Chicago (UIC) is a leading academic institution renowned for its commitment to advancing health sciences through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, UIC harnesses the expertise of its diverse faculty and state-of-the-art facilities to conduct cutting-edge clinical studies aimed at improving patient outcomes. The university's robust infrastructure for clinical research, combined with its dedication to ethical standards and regulatory compliance, positions UIC as a pivotal contributor to the development of new treatments and therapies in various medical fields. Through strategic partnerships and community engagement, UIC strives to translate research findings into real-world applications, enhancing the health and well-being of populations locally and globally.

Locations

Chicago, Illinois, United States

Patients applied

0 patients applied

Trial Officials

Robert W Motl, PhD

Principal Investigator

University of Illinois Chicago

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials